ARCHIVES

NCI Director Andrew von Eschenbach To Resign June 10, Remain As FDA Acting Commissioner.

This article is from The Cancer Letter archive.

Vol. 32 No. 21 | June 2, 2006

Download PDF Visit The Full Archive

Related Articles

HHS Inquiry Triggers Sloppy Stories On Gallo’s Laboratory

July 21, 1989

Tracor Lands Second Biggest NCI Contract-$6.6 Million To Manage Commercial Labs’ Portion Of Bioassay Program

April 19, 1974

Phase III Custirsen/Docetaxel/Prednisone Trial Fails Primary Endpoint of Overall Survival

April 25, 2014

NCAB Approves New Nutrition Task Force With Earmarked Funds

May 28, 1982

LAK/IL-2 Extramural Trials Expanded to 20 More cancers

January 8, 1988

NCI Health Disparities Center Describes “Think Tank” Projects For Policy Change.

April 27, 2001